DUBLIN, June 26 /PRNewswire-FirstCall/ --
- Singapore Laboratory Testing Increases by 149% in Past Six Months
ICON plc (NASDAQ:ICLR: ISIN: IE0005711209), a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, today announced that it has moved its Singapore
central laboratory to a new, larger facility located at Loyang Way, Eastern
Singapore. The new laboratory meets the growth in demand for ICON Central
Laboratories' services in Singapore, which has increased by 149% over the
past six months. The larger facility also enables ICON Central Laboratories
to expand its test menu offerings in the region to include increased esoteric
testing as well as flow cytometry, molecular diagnostics and biomarkers, to
complement the services of ICON's other wholly-owned central laboratories in
Europe, India and the United States.
'As ICON celebrates its tenth year of operation in Singapore, our move to
a larger laboratory signals our continued commitment to the region,'
commented Bob Scott-Edwards, President, ICON Central Laboratories. 'Singapore
has become a regional hub for drug development in Asia-Pacific and we now
have the capacity, the range of testing services and, above all, a highly
experienced team of lab professionals to support the growth of clinical
trials in the region.'
ICON Central Laboratories Singapore supports all major therapeutic areas,
including cardiovascular, oncology, endocrinology and metabolism, and
virology. The laboratory serves as a regional hub for test samples from
Australia, New Zealand, South Korea, Malaysia, Singapore, Taiwan, Japan,
Thailand, Hong Kong, China and Indonesia. ICON Central Laboratories Singapore
received CAP (College of American Pathologists) accreditation in March 2009,
ensuring the highest standards of excellence in laboratory services.
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full service,
global central laboratory services from core facilities in New York, Dublin,
Singapore and India, as well as through quality affiliate laboratories in
China and Japan. An extensive test menu of safety, esoteric and
custom-developed assays, including global flow cytometry, is complemented by
dedicated, sponsor-specific project teams and a single, comprehensive
database for each study as well as a user-friendly, web-based, secure remote
data access system. ICON Central Laboratories also offers a unique service to
manage and compile laboratory data when a client's study requires the use of
local laboratories.
ICON/ICLR-G
For more information, visit http://www.icolabs.com.
US contact:
Courtney Judd
+1-212-445-8365
UK contact:
Erika Aalto
+44(0)20-706-70-214
SOURCE ICON plc